Effect of Lugol's Solution in the Patients With Graves' Disease
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Context: Although some of endocrine surgeons administer Lugol's solution to decrease thyroid
gland vascularity, there is still no agreement on its effectiveness.
Objective: The aims of this clinical trial are to evaluate thyroid blood flow and microvessel
density in the patients with Graves' disease according to the Lugol's solution treatment
preoperatively.
Design: Retrospective clinical trial. Setting: A tertiary referral center. Method: Thirty-six
patients were randomly assigned to preoperative medication with Lugol's solution. Patients in
group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas
patients in group 2 (n=19) didn't receive it.
Main Outcome Measures: Blood flow through the thyroid arteries of patients with Graves'
disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was
assessed immunohistochemically and Western blot analysis using the level of expression of
CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all
patients.